VTE Diagnostic & Exclusion Pathway v6.0 Wells’, PERC & YEARS Synthesis Engine · MEDiscuss.org
! Special Considerations
Active Pregnancy (Or ≤ 6 weeks postpartum)
📈 Master VTE Engine: Select the suspected pathology. The engine dynamically calculates pre-test probability, applies exclusion rules (PERC/YEARS), and generates precise, assay-specific D-Dimer thresholds.
1 Baseline & Vitals

2 Suspected Pathology
📚 Clinical Evidence & ApplicationPathway Architecture

The MEDiscuss VTE Engine automates the diagnostic algorithm to minimise unnecessary imaging and radiation exposure. It first establishes pre-test probability. For ‘Likely’ cases, it recommends immediate imaging (CUS for DVT, CTPA for PE). For ‘Unlikely’ cases, it seamlessly applies exclusion rules (PERC or YEARS) and precisely calculates age-adjusted D-dimer thresholds to safely exclude venous thromboembolism.

The PERC Rule Mandate

The Pulmonary Embolism Rule-out Criteria (PERC) is strictly validated only for patients with a low pre-test probability (Wells’ score ≤ 4). It comprises 8 objective clinical variables. If a low-risk patient is PERC-negative (zero criteria met), PE is excluded with an overwhelmingly high confidence margin, obviating the need for D-dimer testing or CTPA.

⚠ The D-Dimer Assay Unit Trap
Know your lab’s exact assay. D-dimer is reported in either Fibrinogen Equivalent Units (FEU) or D-Dimer Units (DDU). 500 μg/L FEU = 250 μg/L DDU. Applying the Age × 10 formula to a DDU assay will dangerously double the threshold, leading to fatal missed PEs. Always confirm the unit.
The “Alternative Diagnosis” Bias (Wells’ DVT)

Subtracting 2 points for an “alternative diagnosis” heavily skews the result to “Unlikely”. Only select this if you have objective evidence (e.g., visible cellulitis, obvious trauma, ruptured Baker’s cyst on US). Do not select it simply based on an unverified hunch of a “muscle tear”.

Drug Selection Pathways
  • First-Line Therapy: NOACs (Apixaban, Rivaroxaban) are the standard of care for acute VTE. They do not require bridging with LMWH.
  • Cancer-Associated Thrombosis (CAT): Apixaban and Rivaroxaban are preferred over LMWH for convenience, EXCEPT in gastrointestinal (GI) or genitourinary (GU) cancers, where NOACs have unacceptably high rates of mucosal bleeding. Use LMWH for GI/GU cancer patients.
  • Antiphospholipid Syndrome (APS): NOACs are absolutely contraindicated. Use Warfarin (target INR 2.0 to 3.0).
Abbreviations: VTE (Venous Thromboembolism) · DVT (Deep Vein Thrombosis) · PE (Pulmonary Embolism) · PERC (Pulmonary Embolism Rule-out Criteria) · NOAC (Non-Vitamin K Oral Anticoagulant) · LMWH (Low Molecular Weight Heparin) · CUS (Compression Ultrasound) · CTPA (CT Pulmonary Angiography)
⚠ Clinical Disclaimer: These algorithms are clinical decision aids. A numerical score does not replace clinical gestalt. Do not use the PERC rule if clinical suspicion for PE is high despite a low Wells score.
Algorithm References & Evidence Base
  1. Wells PS, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003.
  2. Wells PS, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging. Ann Intern Med. 2001.
  3. Kline JA, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008.
  4. Schouten HJ, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients. BMJ. 2013.
  5. van der Hulle T, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study). Lancet. 2017.
MEDiscuss Clinical Decision Support Suite

Access all evidence-based algorithms, prognostic matrices, and pharmacotherapeutic pathways.

View All Clinical Modules